Novo Nordisk
2025.04.29
22:10
Telemedicine company Hims & Hers partners with Novo Nordisk to expand Wegovy sales
Telemedicine company Hims & Hers announced a long-term partnership with Novo Nordisk on April 29 local time. Americans can now directly access Novo Nordisk pharmacies through the Hims & Hers platform and bundle all doses of Novo Nordisk weight loss drugs Wegovy and Hims & Hers membership, which includes 24-hour care, continuous clinical support and nutritional guidance.
2025.04.17
21:38
Novo Nordisk fell 8% in early trading
Novo Nordisk fell 8% in early trading after its weight loss drug competitor Eli Lilly achieved positive results in a Phase 3 trial of an oral weight loss drug.
2025.04.14
18:56
Novo Nordisk (NVO.N) rose 4.7% in premarket trading as Pfizer abandoned its obesity drug.
2025.04.07
15:05
Novo Nordisk's European shares fell 7% after the Trump administration abandoned a proposal to cover weight loss drugs with Medicare.
15:04
Novo Nordisk's European shares fell 7% as the Trump administration abandoned its proposal to cover weight loss drugs with Medicare
Novo Nordisk's European shares fell 7% after the Trump administration abandoned a proposal to cover weight loss drugs with Medicare.
2025.04.01
16:54
Huadong Medicine: The application for marketing approval of semaglutide injection has been accepted
Huadong Medicine announced that its wholly-owned subsidiary Hangzhou Sino-US Huadong Pharmaceutical Jiangdong Co., Ltd. received the "Acceptance Notice" from the State Food and Drug Administration, and its application for marketing authorization of semaglutide injection has been accepted. The drug is a long-acting glucagon-like peptide-1 receptor agonist, mainly used to control blood sugar in patients with type 2 diabetes and weight management in obese or overweight patients. The original developer of semaglutide injection is Novo Nordisk, and it has been launched in many markets around the world. The total direct investment in the research and development of this drug is approximately 196 million yuan. The acceptance of this listing application marks an important progress in the research and development of the drug, which will help enhance the company's competitiveness in the field of endocrine therapy in the long run.
2025.03.28
23:47
Novo Nordisk buys another weight loss drug for $1 billion
On March 28, Novo Nordisk reached a licensing agreement with biopharmaceutical company Lexicon Pharmaceuticals, under which Novo Nordisk will obtain the global development, production and commercialization rights of Lexicon's LX9851, a drug for the treatment of obesity and related metabolic disorders. The deal is worth up to $1 billion and is Novo Nordisk's second weight loss drug deal this week. On Monday, Novo Nordisk acquired the global rights to China Federal Pharmaceutical's weight loss drug for up to $2 billion.
2025.03.24
20:17
Novo Nordisk (NVO.N) is expanding its $499-a-month weight-loss drug Wegovy to more patients.
18:05
Novo Nordisk (NVO.N) has reached an exclusive licensing agreement with United Laboratories.
2025.03.22
08:12
Eli Lilly launches weight loss drug Mounjaro in India, defeating Novo Nordisk to capture key market
Eli Lilly and Co. launched its diabetes and weight loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk to enter the world's most populous country as it grapples with rising rates of obesity and diabetes. Eli Lilly and Denmark's Novo Nordisk are seeing surging global demand for their innovative weight loss drugs, and investor interest has boosted drugmakers' valuations.
2025.03.12
12:33
Jefferies: Lowered Novo Nordisk's target price from 515 Danish kroner to 450 Danish kroner.
2025.03.06
14:54
Novo Nordisk (NVO.N): Risk costs are expected to be around 35% by 2025 and around 32% in the medium term.
2025.03.03
14:00
Goldman Sachs has included AstraZeneca, Novo Nordisk and Rio Tinto on its European "confidence list".
2025.02.25
08:19
Huatai Securities: There is a large gap in global GLP-1 products, and the M&A wave is expected to continue
Huatai Securities believes that GLP-1 has shown great market potential, and currently only Novo Nordisk and Eli Lilly are the leading MNCs in sales overseas, but they have not yet formed a complete product matrix. Other MNC products are still in the clinical stage, the competition landscape has not yet been finalized, and there is a large gap in products. Since 2004, there have been frequent overseas transactions of domestic GLP-1. We believe that the competitiveness of domestic GLP-1 products is not inferior to that of overseas products. Among them, there are many high-quality assets with leading clinical progress in targets such as GLP-1 oral small molecules, GLP-1/GIP, GLP-1/GIP/GCGR, GLP-1/GCGR/FGF21, and ActRII, which are expected to enter the global market with the help of BD in the future.
2025.02.21
23:12
Novo Nordisk (NVO.N): All doses of semaglutide approved by the U.S. Food and Drug Administration (FDA) are continuing to ship, meeting or exceeding expected U.S. demand.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Apple (AAPL.O): Vietnam is expected to be the country of origin for most iPads, Macs, Apple Watches and Airpods sold in the United States.

2025-05-02

US judge rules Apple violated order to reform App Store

2025-05-01

Shanghai: Using tax support to encourage more innovation and help companies go global

2025-04-30

Ideal Auto's Ring OS is officially open source, and the code is now available for download

2025-04-28

Apple (AAPL.O) had a net profit of US$24.78 billion in the second quarter of fiscal year 2025, compared with market expectations of US$24.26 billion and US$23.636 billion in the same period last year.

2025-05-02

ASIA TECH WIRE

Grasp technology trends

Download